Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, Hebei Province, China.
Hebei Province Hospital of Traditional Chinese Medicine, Shijiazhuang, Hebei Province, China.
Sci Rep. 2023 Jul 4;13(1):10767. doi: 10.1038/s41598-023-37902-7.
Totally implantable venous access devices (TIVADs) have been widely used for many years in the management of patients suffering from cancer. Thrombotic occlusion is the most common functional complication in the off-treatment period. This study aims to investigate the incidence of and risk factors for TIVADs-related thrombotic occlusion in patients with breast cancer. The clinical data of 1586 eligible patients with breast cancer with TIVADs at the Fourth Affiliated Hospital of Hebei Medical University from 1 January 2019 to 31 August 2021 were analysed. Thrombotic occlusion was confirmed by angiography with signs of partial or total occlusion. Thrombotic occlusion occurred in 96 (6.1%) cases. Multivariable logistic regression analysis showed that the insertion site of the catheter (P = 0.004), size of the catheter (P < 0.001), and indwelling time (P < 0.001) were significant factors for thrombotic occlusion. Insertion in the right internal jugular vein, smaller catheter size and shorter indwelling time can lower the incidence of thrombotic occlusion in breast cancer patients with TIVADs in the off-treatment period.
完全植入式静脉通路装置（TIVAD）在癌症患者的治疗中已被广泛应用多年。血栓闭塞是治疗间歇期最常见的功能并发症。本研究旨在探讨乳腺癌患者 TIVAD 相关血栓闭塞的发生率和危险因素。对 2019 年 1 月 1 日至 2021 年 8 月 31 日在河北医科大学第四附属医院接受 TIVAD 的 1586 例乳腺癌患者的临床资料进行分析。采用血管造影术确认血栓闭塞，表现为部分或完全闭塞。结果 96 例（6.1%）发生血栓闭塞。多变量 logistic 回归分析显示，导管插入部位（P=0.004）、导管大小（P<0.001）和留置时间（P<0.001）是血栓闭塞的显著影响因素。右侧颈内静脉置管、较小的导管尺寸和较短的留置时间可降低治疗间歇期乳腺癌患者 TIVAD 血栓闭塞的发生率。
